Roche has stopped dosing patients in a Phase 3 study of an investigational drug for Huntington’s disease, a rare genetic condition that causes nerve cells in the brain to break down. The drug, tominersen, is an antisense therapy designed to reduce the production of all forms of huntingtin protein, including its mutated variant. The trial was the largest study to date in patients with this disease.
